Patients suffering from a rare autoimmune disorder could actually be the key for a new promising type of antibodies. These are the findings of researchers from ImmunoQure and different European universities, now published in Cell.
More than 40 years ago, the development of monoclonal antibodies really pushed the class of biologics forward.
Research on antibodies is still strong now, with new developments in cancer immunotherapies and new spins on these agents, from bispecific antibodies (like those developed by Genmab and Merus) to alpaca-derived mini-antibodies. Now, autoantibodies may be joining the list of exciting developments in the field.
Broadly, the term autoantibody describes any antibody that the human body produces against its own proteins – so the ‘bad guy‘ in serious autoimmune disorders.